Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation.

Zumsteg ZS, Luu M, Kim S, Tighiouart M, Mita A, Scher KS, Lu DJ, Shiao SL, Mallen-St Clair J, Ho AS.

Ann Oncol. 2019 Oct 1;30(10):1669. doi: 10.1093/annonc/mdz172. No abstract available.

PMID:
31168574
2.

Accurate needle-free assessment of myocardial oxygenation for ischemic heart disease in canines using magnetic resonance imaging.

Yang HJ, Oksuz I, Dey D, Sykes J, Klein M, Butler J, Kovacs MS, Sobczyk O, Cokic I, Slomka PJ, Bi X, Li D, Tighiouart M, Tsaftaris SA, Prato FS, Fisher JA, Dharmakumar R.

Sci Transl Med. 2019 May 29;11(494). pii: eaat4407. doi: 10.1126/scitranslmed.aat4407.

PMID:
31142677
3.

Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.

Tighiouart M.

J R Stat Soc Ser C Appl Stat. 2019 Jan;68(1):235-250. doi: 10.1111/rssc.12294. Epub 2018 Jun 22.

PMID:
30745708
4.

Survival Impact of Adjuvant Therapy in Salivary Gland Cancers following Resection and Neck Dissection.

Aro K, Ho AS, Luu M, Kim S, Tighiouart M, Yoshida EJ, Mallen-St Clair J, Shiao SL, Leivo I, Zumsteg ZS.

Otolaryngol Head Neck Surg. 2019 Jun;160(6):1048-1057. doi: 10.1177/0194599819827851. Epub 2019 Feb 5.

PMID:
30721113
5.

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.

Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D, Rokhsar S, Scher K, Klempner SJ, Noe P, Davis MJ, Wachsman A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar A.

EBioMedicine. 2019 Feb;40:375-381. doi: 10.1016/j.ebiom.2018.12.060. Epub 2019 Jan 8.

6.

Comparison between continuous and discrete doses for model based designs in cancer dose finding.

Diniz MA, Tighiouart M, Rogatko A.

PLoS One. 2019 Jan 9;14(1):e0210139. doi: 10.1371/journal.pone.0210139. eCollection 2019.

7.

Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation.

Zumsteg ZS, Luu M, Kim S, Tighiouart M, Mita A, Scher KS, Lu DP, Shiao SL, Mallen-St Clair J, Ho AS.

Ann Oncol. 2019 Jan 1;30(1):76-84. doi: 10.1093/annonc/mdy490.

PMID:
30395159
8.

Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents.

Jimenez JL, Tighiouart M, Gasparini M.

Biom J. 2019 Mar;61(2):319-332. doi: 10.1002/bimj.201700166. Epub 2018 May 28.

9.

Quantitative survival impact of composite treatment delays in head and neck cancer.

Ho AS, Kim S, Tighiouart M, Mita A, Scher KS, Epstein JB, Laury A, Prasad R, Ali N, Patio C, Clair JM, Zumsteg ZS.

Cancer. 2018 Aug 1;124(15):3154-3162. doi: 10.1002/cncr.31533. Epub 2018 May 9.

10.

Development of a novel salivary gland cancer lymph node staging system.

Aro K, Ho AS, Luu M, Kim S, Tighiouart M, Clair JM, Yoshida EJ, Shiao SL, Leivo I, Zumsteg ZS.

Cancer. 2018 Aug 1;124(15):3171-3180. doi: 10.1002/cncr.31535. Epub 2018 May 9.

11.

Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification.

Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, Shiao SL, Tighiouart M, Ho AS, Zumsteg ZS.

Head Neck. 2018 Jun;40(6):1228-1236. doi: 10.1002/hed.25100. Epub 2018 Feb 8.

PMID:
29417700
12.

A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.

Diniz MA, Kim S, Tighiouart M.

J Probab Stat. 2018;2018. pii: 8654173. doi: 10.1155/2018/8654173. Epub 2018 Nov 1.

13.

Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer.

Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, Scher KS, Laury A, Prasad R, Shiao SL, Ali N, Patio C, Mallen-St Clair J, Van Eyk JE, Zumsteg ZS.

JAMA Oncol. 2018 Jul 1;4(7):985-989. doi: 10.1001/jamaoncol.2017.3852.

14.

Facility Volume and Survival in Nasopharyngeal Carcinoma.

Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, Shiao SL, Tighiouart M, Lee NY, Ho AS, Zumsteg ZS.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):408-417. doi: 10.1016/j.ijrobp.2017.09.038. Epub 2017 Sep 28.

PMID:
29100787
15.

Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer.

Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, Scher KS, Laury A, Prasad R, Shiao SL, Van Eyk JE, Zumsteg ZS.

J Clin Oncol. 2017 Nov 1;35(31):3601-3609. doi: 10.1200/JCO.2016.71.1176. Epub 2017 Sep 7.

16.

A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.

Tighiouart M, Cook-Wiens G, Rogatko A.

J Biopharm Stat. 2018;28(3):562-574. doi: 10.1080/10543406.2017.1372774. Epub 2017 Oct 6.

17.

Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base.

Zumsteg ZS, Luu M, Yoshida EJ, Kim S, Tighiouart M, David JM, Shiao SL, Mita AC, Scher KS, Sherman EJ, Lee NY, Ho AS.

Cancer. 2017 Dec 1;123(23):4583-4593. doi: 10.1002/cncr.30933. Epub 2017 Aug 17.

18.

Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.

David JM, Ho AS, Luu M, Yoshida EJ, Kim S, Mita AC, Scher KS, Shiao SL, Tighiouart M, Zumsteg ZS.

Cancer. 2017 Oct 15;123(20):3933-3942. doi: 10.1002/cncr.30843. Epub 2017 Jun 22.

19.

Arterial CO2 as a Potent Coronary Vasodilator: A Preclinical PET/MR Validation Study with Implications for Cardiac Stress Testing.

Yang HJ, Dey D, Sykes J, Klein M, Butler J, Kovacs MS, Sobczyk O, Sharif B, Bi X, Kali A, Cokic I, Tang R, Yumul R, Conte AH, Tsaftaris SA, Tighiouart M, Li D, Slomka PJ, Berman DS, Prato FS, Fisher JA, Dharmakumar R.

J Nucl Med. 2017 Jun;58(6):953-960. doi: 10.2967/jnumed.116.185991. Epub 2017 Mar 2.

20.

Pitfalls and Rewards for Implementing Ocular Motor Testing in Acute Vestibular Syndrome: A Pilot Project.

Dumitrascu OM, Torbati S, Tighiouart M, Newman-Toker DE, Song SS.

Neurologist. 2017 Mar;22(2):44-47. doi: 10.1097/NRL.0000000000000106.

21.

Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.

Diniz MA, Quanlin-Li, Tighiouart M.

J Biom Biostat. 2017;8(6). pii: 381. doi: 10.4172/2155-6180.1000381. Epub 2017 Nov 27.

22.

Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.

Zumsteg ZS, Kim S, David JM, Yoshida EJ, Tighiouart M, Shiao SL, Scher K, Mita A, Sherman EJ, Lee NY, Ho AS.

Cancer. 2017 May 1;123(9):1555-1565. doi: 10.1002/cncr.30508. Epub 2016 Dec 21.

23.

Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding.

Rogatko A, Cook-Wiens G, Tighiouart M, Piantadosi S.

Entropy (Basel). 2015 Aug;17(8):5288-5303. Epub 2015 Jul 27.

24.

A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.

Tighiouart M, Li Q, Rogatko A.

Stat Med. 2017 Jan 30;36(2):280-290. doi: 10.1002/sim.6961. Epub 2016 Apr 7.

25.

Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy.

Osipov A, Naziri J, Hendifar A, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M, Annamalai A, Nissen NN, Tuli R.

J Gastrointest Oncol. 2016 Apr;7(2):239-47. doi: 10.3978/j.issn.2078-6891.2015.109.

26.

A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials.

Tighiouart M, Li Q, Piantadosi S, Rogatko A.

Am J Biostat. 2016;6(1):1-11. doi: 10.3844/amjbsp.2016.1.11. Epub 2016 Aug 25.

27.

Native T1 Mapping by 3-T CMR Imaging for Characterization of Chronic Myocardial Infarctions.

Kali A, Choi EY, Sharif B, Kim YJ, Bi X, Spottiswoode B, Cokic I, Yang HJ, Tighiouart M, Conte AH, Li D, Berman DS, Choi BW, Chang HJ, Dharmakumar R.

JACC Cardiovasc Imaging. 2015 Sep;8(9):1019-1030. doi: 10.1016/j.jcmg.2015.04.018. Epub 2015 Aug 19.

28.

Iron-Sensitive Cardiac Magnetic Resonance Imaging for Prediction of Ventricular Arrhythmia Risk in Patients With Chronic Myocardial Infarction: Early Evidence.

Cokic I, Kali A, Yang HJ, Yee R, Tang R, Tighiouart M, Wang X, Jackman WS, Chugh SS, White JA, Dharmakumar R.

Circ Cardiovasc Imaging. 2015 Aug;8(8). pii: e003642. doi: 10.1161/CIRCIMAGING.115.003642.

29.

Analysis of the bypass angioplasty revascularization investigation trial using a multistate model of clinical outcomes.

Zhang X, Li Q, Rogatko A, Tighiouart M, Hardison RM, Brooks MM, Kelsey SF, Kaul S, Bairey Merz CN.

Am J Cardiol. 2015 Apr 15;115(8):1073-9. doi: 10.1016/j.amjcard.2015.01.543. Epub 2015 Feb 2.

30.

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.

Owonikoko TK, Ramalingam SS, Miller DL, Force SD, Sica GL, Mendel J, Chen Z, Rogatko A, Tighiouart M, Harvey RD, Kim S, Saba NF, Pickens A, Behera M, Fu RW, Rossi MR, Auffermann WF, Torres WE, Bechara R, Deng X, Sun SY, Fu H, Gal AA, Khuri FR.

Clin Cancer Res. 2015 Apr 15;21(8):1859-68. doi: 10.1158/1078-0432.CCR-14-1998. Epub 2015 Feb 11.

31.

Increasing percutaneous coronary interventions for ST-segment elevation myocardial infarction in the United States: progress and opportunity.

Shah RU, Henry TD, Rutten-Ramos S, Garberich RF, Tighiouart M, Bairey Merz CN.

JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):139-146. doi: 10.1016/j.jcin.2014.07.017. Epub 2014 Oct 30.

32.

Cardiac steatosis and left ventricular dysfunction in HIV-infected patients treated with highly active antiretroviral therapy.

Nelson MD, Szczepaniak LS, LaBounty TM, Szczepaniak E, Li D, Tighiouart M, Li Q, Dharmakumar R, Sannes G, Fan Z, Yumul R, Hardy WD, Hernandez Conte A.

JACC Cardiovasc Imaging. 2014 Nov;7(11):1175-7. doi: 10.1016/j.jcmg.2014.04.024. Epub 2014 Nov 10. No abstract available.

33.

Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.

Tighiouart M, Piantadosi S, Rogatko A.

Stat Med. 2014 Sep 28;33(22):3815-29. doi: 10.1002/sim.6201. Epub 2014 May 13.

34.

Escalation with overdose control using time to toxicity for cancer phase I clinical trials.

Tighiouart M, Liu Y, Rogatko A.

PLoS One. 2014 Mar 24;9(3):e93070. doi: 10.1371/journal.pone.0093070. eCollection 2014.

35.

Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.

Shao C, Liao CP, Hu P, Chu CY, Zhang L, Bui MH, Ng CS, Josephson DY, Knudsen B, Tighiouart M, Kim HL, Zhau HE, Chung LW, Wang R, Posadas EM.

PLoS One. 2014 Feb 14;9(2):e88967. doi: 10.1371/journal.pone.0088967. eCollection 2014.

36.

A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.

Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, Karlan BY, Orsulic S.

Clin Cancer Res. 2014 Feb 1;20(3):711-23. doi: 10.1158/1078-0432.CCR-13-1256. Epub 2013 Nov 11.

37.

The Integrated Web Portal for Escalation with Overdose Control (EWOC).

Wang H, Tighiouart M, Huang SC, Berel D, Cook-Wiens G, Bresee C, Li Q, Rogatko A.

Open Med Inform J. 2013 May 31;7:18-23. doi: 10.2174/1874431120130427001. Print 2013.

38.

Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma.

Fan S, Müller S, Chen ZG, Pan L, Tighiouart M, Shin DM, Khuri FR, Sun SY.

Cancer Biol Ther. 2013 Apr;14(4):365-9. doi: 10.4161/cbt.23636. Epub 2013 Jan 28.

39.

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.

Harvey RD, Owonikoko TK, Lewis CM, Akintayo A, Chen Z, Tighiouart M, Ramalingam SS, Fanucchi MP, Nadella P, Rogatko A, Shin DM, El-Rayes B, Khuri FR, Kauh JS.

Br J Cancer. 2013 Mar 5;108(4):762-5. doi: 10.1038/bjc.2012.604. Epub 2013 Jan 15.

40.

The pivotal role of integrin β1 in metastasis of head and neck squamous cell carcinoma.

Wang D, Müller S, Amin AR, Huang D, Su L, Hu Z, Rahman MA, Nannapaneni S, Koenig L, Chen Z, Tighiouart M, Shin DM, Chen ZG.

Clin Cancer Res. 2012 Sep 1;18(17):4589-99. doi: 10.1158/1078-0432.CCR-11-3127. Epub 2012 Jul 24.

41.

A pragmatic approach using magnetic resonance imaging to treat ischemic strokes of unknown onset time in a thrombolytic trial.

Song SS, Latour LL, Ritter CH, Wu O, Tighiouart M, Hernandez DA, Ku KD, Luby M, Warach S.

Stroke. 2012 Sep;43(9):2331-5. doi: 10.1161/STROKEAHA.111.630947. Epub 2012 Jun 12.

42.

Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.

Chen Z, Tighiouart M, Kowalski J.

Contemp Clin Trials. 2012 Sep;33(5):949-58. doi: 10.1016/j.cct.2012.04.007. Epub 2012 Apr 25.

43.

A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.

Sinha R, Kaufman JL, Khoury HJ Jr, King N, Shenoy PJ, Lewis C, Bumpers K, Hutchison-Rzepka A, Tighiouart M, Heffner LT, Lechowicz MJ, Lonial S, Flowers CR.

Cancer. 2012 Jul 15;118(14):3538-48. doi: 10.1002/cncr.26660. Epub 2012 Jan 3.

44.

Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.

Arellano M, Pakkala S, Langston A, Tighiouart M, Pan L, Chen Z, Heffner LT, Lonial S, Winton E, Khoury HJ.

Cancer. 2012 Nov 1;118(21):5278-82. doi: 10.1002/cncr.27494. Epub 2012 Apr 19.

45.

Med1 plays a critical role in the development of tamoxifen resistance.

Nagalingam A, Tighiouart M, Ryden L, Joseph L, Landberg G, Saxena NK, Sharma D.

Carcinogenesis. 2012 Apr;33(4):918-30. doi: 10.1093/carcin/bgs105. Epub 2012 Feb 16.

46.

Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer.

Xu J, Müller S, Nannapaneni S, Pan L, Wang Y, Peng X, Wang D, Tighiouart M, Chen Z, Saba NF, Beitler JJ, Shin DM, Chen ZG.

Eur J Cancer. 2012 Jul;48(11):1682-91. doi: 10.1016/j.ejca.2011.12.029. Epub 2012 Feb 15.

47.

Localization-specific LKB1 loss in head and neck squamous cell carcinoma metastasis.

Kline ER, Muller S, Pan L, Tighiouart M, Chen ZG, Marcus AI.

Head Neck. 2011 Oct;33(10):1501-12. doi: 10.1002/hed.21638. Epub 2010 Dec 9.

PMID:
21928424
48.

A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.

Zhang H, Yun S, Batuwangala TD, Steward M, Holmes SD, Pan L, Tighiouart M, Shin HJ, Koenig L, Park W, Rycroft D, Nannapaneni S, Wang Y, Chen ZG, Shin DM.

Int J Cancer. 2012 Aug 15;131(4):956-69. doi: 10.1002/ijc.26427. Epub 2011 Nov 19.

49.

Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.

Hurwitz SJ, Zhang H, Yun S, Batuwangala TD, Steward M, Holmes SD, Rycroft D, Pan L, Tighiouart M, Shin HJ, Koenig L, Wang Y, Chen ZG, Shin DM.

Cancer Chemother Pharmacol. 2012 Mar;69(3):577-90. doi: 10.1007/s00280-011-1713-x. Epub 2011 Sep 13.

PMID:
21913035
50.

Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia.

Arellano M, Bernal-Mizrachi L, Pan L, Tighiouart M, Souza L, Guo X, McLemore M, Lima L, Sunay S, Heffner LT, Chen Z, Chen GZ, Langston A, Winton E, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):427-32. doi: 10.1016/j.clml.2011.03.035. Epub 2011 May 5.

PMID:
21729688

Supplemental Content

Loading ...
Support Center